Results 1 - 10 of 77

< 1 2 3 ... 7 8 >

• Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer, Cancer Chemotherapy and Pharmacology

  [DOI: 10.1007/s00280-014-2609-3]
  
• Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT), BMC Cancer

  [DOI: 10.1186/s12885-015-1470-z]
  
• Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights, Journal of Hematology & Oncology

  [DOI: 10.1186/1756-8722-3-17]
  
• Mechanisms and Potential Therapies for Acquired Resistance to Inhibitors Targeting the Raf or MEK Kinases in Cancer, Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

  [DOI: 10.1007/978-1-4614-7070-0_3]
  
• Targeting Oncogenic BRAF in Human Cancer, Therapeutic Kinase Inhibitors

  [DOI: 10.1007/82_2011_162]
  
• Current and Future Trials of Targeted Therapies in Cutaneous Melanoma, Impact of Genetic Targets on Cancer Therapy

  [DOI: 10.1007/978-1-4614-6176-0_10]
  
• Advances in Ovarian Cancer and Ongoing Clinical Trials, Gynecological Cancers

  [DOI: 10.1007/978-3-319-32907-9_4]
  
• Treatment of Uveal Melanoma, Melanoma

  [DOI: 10.1007/978-3-319-22539-5_12]
  
• KRAS-Mutant Lung Cancers in the Era of Targeted Therapy, Lung Cancer and Personalized Medicine

  [DOI: 10.1007/978-3-319-24223-1_8]
  
• Targeted Therapy in Melanoma, Genetics of Melanoma

  [DOI: 10.1007/978-1-4939-3554-3_11]